Business
Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
Quarterly investor conference call and webcast scheduled for Tuesday, February 28 at 4:30 p.m. ETArcutis management will also participate in the Cowen 43rd
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"Quarterly investor conference call and webcast scheduled for Tuesday, February 28 at 4:30 p.m. ETArcutis management will also participate in the Cowen 43rd Annual Healthcare Conference in March WESTLAKE VILLAGE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 4:30 p.m. ET on Tuesday, February 28, 2022 to report its fourth quarter and full year financial results, and provide a business update. A live webcast of the call and the presentation material will be available on the “Events” section of the Company’s investor website. An archived replay of the webcast will be available on the Arcutis investor website following the conference. Arcutis also announced its participation for an upcoming investor conference. Details for the company’s participation are as follows: Cowen 43rd Annual Health Care Conference Fireside Chat Date/Time: Tuesday, March 7 at 10:30 a.m. ETDermatology Panel Discussion Date/Time: Tuesday, March 7 at 12:50 p.m. ET A live webcast for each of these events may be accessed at the “Events” section of the Company’s website. About ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio that harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, seborrheic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, and Twitter. Forward-Looking StatementsThis press release contains \"forward-looking\" statements. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual...